Literature DB >> 12782582

A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells.

Mark M Fuster1, Jillian R Brown, Lianchun Wang, Jeffrey D Esko.   

Abstract

Clustered presentation of sialyl Lewis X (sLe(X)) on tumor cell mucins is thought to facilitate metastasis through binding to selectin adhesion receptors expressed on platelets, leukocytes and endothelial cells. Thus, interfering with sLe(X) assembly might provide a chemotherapeutic method for treating metastatic disease. Prior studies have shown that peracetylated disaccharides can act in cells as substrates for the assembly of oligosaccharides related to sLe(X) synthesis, and the assembly of oligosaccharides on the disaccharides diverts the assembly of sLe(X) from endogenous cell surface glycoconjugates. Here, we show that treatment of cultured human adenocarcinoma cells with micromolar concentrations of the peracetylated disaccharide, (Ac)(6)GlcNAcbeta1,3Galbeta-O-naphthalenemethanol (AcGnG-NM) reduces the expression of sLe(X) and diminishes binding in vitro to selectin-coated dishes, thrombin-activated platelets, and tumor necrosis factor alpha-activated endothelial cells. Altering glycosylation in this way significantly reduced the ability of tumor cells to distribute to the lungs of wild-type mice over a 3-h period after i.v. injection. No significant difference in biodistribution was noted after the injection of AcGnG-NM-treated tumor cells into P-selectin deficient mice, although the extent of lung seeding was reduced compared with that in wild-type mice. In vitro, we demonstrate that normal mouse platelets, but not P-selectin-deficient platelets, bound to control tumor cells and protected them from leukocyte-mediated cytolysis. Conversely, treatment of tumor cells with disaccharide markedly reduced the ability of normal platelets to protect them from cytolysis. Finally, in an experimental metastasis model, we show that treatment of tumor cells with the disaccharide markedly reduced their lung colonization potential after injection into severe combined immunodeficient mice. These findings suggest that this compound may represent a novel class of chemotherapeutic agents for prevention and treatment of metastatic disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12782582

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

Review 1.  Platelets: linking hemostasis and cancer.

Authors:  Shashank Jain; John Harris; Jerry Ware
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

Review 2.  Simple sugars to complex disease--mucin-type O-glycans in cancer.

Authors:  Matthew R Kudelka; Tongzhong Ju; Jamie Heimburg-Molinaro; Richard D Cummings
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

3.  Specificity of β1,4-galactosyltransferase inhibition by 2-naphthyl 2-butanamido-2-deoxy-1-thio-β-D-glucopyranoside.

Authors:  Yin Gao; Carmen Lazar; Walter A Szarek; Inka Brockhausen
Journal:  Glycoconj J       Date:  2010-10-26       Impact factor: 2.916

4.  Glycomic profiling of invasive and non-invasive breast cancer cells.

Authors:  John A Goetz; Yehia Mechref; Pilsoo Kang; Meei-Huey Jeng; Milos V Novotny
Journal:  Glycoconj J       Date:  2008-08-28       Impact factor: 2.916

Review 5.  Metabolic glycoengineering bacteria for therapeutic, recombinant protein, and metabolite production applications.

Authors:  Christopher T Saeui; Esteban Urias; Lingshu Liu; Mohit P Mathew; Kevin J Yarema
Journal:  Glycoconj J       Date:  2015-05-01       Impact factor: 2.916

6.  Fluorinated per-acetylated GalNAc metabolically alters glycan structures on leukocyte PSGL-1 and reduces cell binding to selectins.

Authors:  Dhananjay D Marathe; Alexander Buffone; E V Chandrasekaran; Jun Xue; Robert D Locke; Mehrab Nasirikenari; Joseph T Y Lau; Khushi L Matta; Sriram Neelamegham
Journal:  Blood       Date:  2009-12-08       Impact factor: 22.113

7.  Immobilized surfactant-nanotube complexes support selectin-mediated capture of viable circulating tumor cells in the absence of capture antibodies.

Authors:  Michael J Mitchell; Carlos A Castellanos; Michael R King
Journal:  J Biomed Mater Res A       Date:  2015-03-30       Impact factor: 4.396

8.  Development of orally active inhibitors of protein and cellular fucosylation.

Authors:  Nicole M Okeley; Stephen C Alley; Martha E Anderson; Tamar E Boursalian; Patrick J Burke; Kim M Emmerton; Scott C Jeffrey; Kerry Klussman; Che-Leung Law; Django Sussman; Brian E Toki; Lori Westendorf; Weiping Zeng; Xinqun Zhang; Dennis R Benjamin; Peter D Senter
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

9.  Characterization of Lewis lung clonal variants in a model of syngeneic pulmonary murine metastases.

Authors:  Bill T Storey; H Keith Pittman; Joseph F Christian; Carl E Haisch; Kathryn M Verbanac
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

10.  Glycan-related gene expression signatures in human metastatic hepatocellular carcinoma cells.

Authors:  Xiaonan Kang; Nian Wang; Chen Pei; Lu Sun; Ruixia Sun; Jie Chen; Yinkun Liu
Journal:  Exp Ther Med       Date:  2011-12-23       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.